 BioCardia, Inc., BCDA, a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today announced that the Company has resumed cases in the CardiAMP Heart Failure Trial. The first patient procedure completed since elective procedures were paused due to COVID-19 took place at Morton Plant Hospital in Clearwater, Florida this month. We are pleased to be able to resume enrollment at several sites for our lead clinical program and look forward to cases taking place in July and August, said BioCardia CEO Peter Altman, PhD. 